Please use this identifier to cite or link to this item:
|Title:||The clinical research enterprise in critical care: what's right, what's wrong, and what's ahead?||Austin Authors:||Reade, Michael C;Angus, Derek C||Affiliation:||Department of Intensive Care Medicine (MCR), Austin Hospital, University of Melbourne, Melbourne, Victoria, Australia||Issue Date:||1-Jan-2009||Publication information:||Critical Care Medicine; 37(1 Suppl): S1-9||Abstract:||Intensivists have been remarkably successful in using randomized controlled trials to assess aspects of current practice. Unfortunately, this success has not been mirrored in trials of new pharmacotherapy, despite convincing pathophysiological rationales and encouraging preliminary studies. Misunderstandings of biological processes and flawed early clinical studies have led to the almost universal failure of fundamentally new treatments subjected to large phase III trials, despite their sound methodology. Compounding these problems is the tendency for new approaches to be either implemented widely on the basis of relatively poor studies or ignored despite strong supporting evidence. Having mastered the principles of evidence-based medicine in assessing existing therapy, intensivists have established a strong foundation. Critical care medicine must now embrace the challenge of translating a more solid understanding of basic disease mechanisms into widely implemented treatments.||Gov't Doc #:||19104206||URI:||http://ahro.austin.org.au/austinjspui/handle/1/10734||DOI:||10.1097/CCM.0b013e318192074c||Journal:||Critical Care Medicine||URL:||https://pubmed.ncbi.nlm.nih.gov/19104206||Type:||Journal Article||Subjects:||Biomedical Research.organization & administration
Clinical Trials as Topic
Research Support as Topic
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.